Recurrent Hypoglycemia Triggered by Sorafenib Therapy in a Patient with Hemangiopericytoma.

Si Won Lee; Eun Kyung Lee; Tak Yun; Young-Woong Won; Eun Jeong Ko; Mihong Choi; Sang Il Choi; Sun Seob Park; Eun Kyung Hong

Targeted therapy has been proven to be one of the most effective cancer treatments. However, some endocrine disorders can occur during treatment with targeted agents. We report the case of a patient who exhibited a wax and wane pattern of hypoglycemia that was attributed to sorafenib therapy. A 32-year-old woman with metastatic hemangiopericytoma visited the emergency department in a stuporous state. Nonhyperinsulinemic hypoglycemia was diagnosed, was exacerbated shortly after sorafenib therapy, and was improved by the cessation of sorafenib with additional glucocorticoid therapy. Patients with metastatic hemangiopericytoma should be carefully monitored with particular attention to hypoglycemia when sorafenib therapy is initiated.

HYPOGLYCEMIA; DISEASE relapse; ENDOCRINE diseases; SARCOMA; CANCER treatment; GLUCOCORTICOIDS; THERAPEUTICS

Endocrinology & Metabolism, 2014, Vol 29, Issue 2, p202

2093-596X

Academic Journal

10.3803/EnM.2014.29.2.202